Skip to main content
logo
Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
12.08
-0.12 (-0.98%)
At close: Sep 11, 2026, 4:00 PM EDT
11.96
-0.12 (-0.99%)
After-hours: Sep 11, 2026, 4:10 PM EDT

Lyell Immunopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
2966541874898651,861
Market Cap Growth
17.18%249.70%-61.73%-43.52%-53.52%-
Enterprise Value
115387-215-45182992
Last Close Price
11.9630.7812.8038.8069.40154.80

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
10854.8718163.583065.303758.6610.22174.77
PB Ratio
1.202.640.490.751.042.00
P/TBV Ratio
1.252.640.490.751.042.00

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
4136.3510759.39--2.1593.15

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.200.210.150.100.080.07
Net Debt / Equity Ratio
-0.78-0.79-0.85-0.76-0.77-0.89
Net Debt / EBITDA Ratio
1.001.051.632.223.804.15
Net Debt / FCF Ratio
1.351.301.993.003.324.33
Asset Turnover
00000.080.01
Quick Ratio
5.125.006.8915.8217.2913.15
Current Ratio
5.365.287.0616.0717.5913.40
Return on Equity (ROE)
-93.28%-86.98%-66.10%-31.53%-20.77%-30.36%
Return on Assets (ROA)
-34.18%-29.83%-22.05%-18.18%-11.32%-13.11%
Return on Capital Employed (ROCE)
-70.20%-68.20%-50.10%-34.30%-20.80%-19.80%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-84.78%-41.97%-183.44%-48.02%-21.17%-13.44%
FCF Yield
-45.71%-23.06%-87.10%-34.05%-22.40%-10.30%
Buyback Yield / Dilution
-49.16%-30.74%-4.18%-1.58%-81.79%-925.18%
SEC Filings: 10-K · 10-Q